NYSE: FOLD - Amicus Therapeutics, Inc.

Yield per half year: -36.2%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Amicus Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Amicus Therapeutics, Inc.

Amicus Therapeutics, Inc., биотехнологическая компания, занимается открытием, разработкой и коммерциализацией методов лечения целого ряда редких и орфанных заболеваний. Компания предлагает Галафолд, перорально вводимый фармакологический компаньон с малой молекулой для лечения болезни Фабри. Он также проводит фазу 3 (ATB200-03) клинического исследования AT-GAA для болезни Помпе. Компания имеет соглашения о сотрудничестве и лицензии с Национальной детской больницей и Университетом Пенсильвании. Amicus Therapeutics, Inc. была основана в 2002 году со штаб-квартирой в Крэнбери, штат Нью-Джерси.

Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2007-05-31
ISIN US03152W1099
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Сайт http://amicusrx.com
Цена ао 8.62
Change price per day: +2.08% (7.2)
Change price per week: +7.61% (6.83)
Change price per month: -13.73% (8.52)
Change price per 3 month: -23.52% (9.61)
Change price per half year: -36.2% (11.52)
Change price per year: -27.73% (10.17)
Change price per 3 year: +9.05% (6.74)
Change price per 5 year: -50.2% (14.76)
Change price per 10 year: -46.55% (13.75)
Change price per year to date: -25% (9.8)
All parameters

Underestimation

Title Value Grade
P/S 5.42 2
P/BV 14.76 1
P/E 0 0
EV/EBITDA 105.28 1
Total: 2.25

Efficiency

Title Value Grade
ROA, % -7.18 0
ROE, % -31.68 0
Total: 1

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA 15.1 0
Total: 4.6

Growth impulse

Title Value Grade
Yield Revenue, % 102.49 10
Yield Ebitda, % -112.63 0
Yield EPS, % -82.77 0
Total: 2
More

Institutions Volume Share, %
Vanguard Group Inc 28492486 9.65
Perceptive Advisors LLC 28057456 9.5
Avoro Capital Advisors LLC 27400000 9.28
Blackrock Inc. 22988139 7.78
JP Morgan Chase & Company 17848531 6.04
Wellington Management Group, LLP 15190024 5.14
Redmile Group, LLC 14828321 5.02
Morgan Stanley 13327897 4.51
State Street Corporation 13163085 4.46
William Blair Investment Management, LLC 11647026 3.94

ETFShare, %Profitability for 1 year, %Dividends, %
Future Tech ETF 0.32442 426.34 0.8416
Principal Healthcare Innovators ETF 0.32442 618.5 0.8416
iShares Morningstar Small-Cap Growth ETF 0.08878 596.94 0.72598
iShares Morningstar Small-Cap ETF 0.06446 391.25 1.60498
iShares Morningstar Small-Cap Value ETF 0.0394 197.28 2.50476
0.17446.061.3



Head Job title Payment Year of birth
Mr. Bradley L. Campbell M.B.A. CEO, President & Director 984.09k 1976 (49 years)
Ms. Ellen S. Rosenberg Chief Legal Officer & Corporate Secretary 733.94k 1963 (62 years)
Ms. Samantha Prout Chief Accounting Officer & Controller N/A 1978 (47 years)
Andrew Faughnan Senior Director of Investor Relations N/A
Mr. David M. Clark Chief People Officer 701.39k 1976 (49 years)
Dr. Jill Weimer Ph.D. Chief Science Officer N/A
Mr. Simon Nicolas Reade Harford Chief Financial Officer N/A 1960 (65 years)
Mr. Patrik S. Florencio Esq. Global Chief Compliance & Risk Officer N/A
Ms. Diana Moore Head of Global Corporate Communications N/A
Dr. Jeffrey P. Castelli Ph.D. Chief Development Officer 1972 (53 years)

Address: United States, Philadelphia, 3675 Market Street - open in Google maps, open in Yandex maps
Website: http://amicusrx.com